Results published today in @NEJM underscore our determination @JNJInnovMed to push the boundaries of science and improve the treatment of EGFR-mutated non-small cell lung cancer. https://t.co/4wMpGbwetD #MyCompany #JNJOncology

Patients with #LungCancer deserve progress on both outcomes and treatment experience. At #WCLC25, @JNJInnovMed is sharing new data that brings us closer to that goal: https://t.co/CNpStIynTI

Lung cancer remains one of the toughest cancers to treat, but research is helping shift what’s possible. This #WorldLungCancerDay, I’m reflecting on how far science has come and how much more we still need to do for people with this disease: https://t.co/tKtkWsVScS #JNJOncology

As #ASCO25 draws to a close I am leaving Chicago inspired by the amazing work being done by researchers to help patients with cancer around the world. This is truly one of the #BreathtakingMoments of working in oncology. Until next time ASCO!

Grateful to @JNJInnovation for the opportunity to be the lead author on #COCOON trial #PRO data at #ASCO25. It meant a lot to be a co-investigator and true partner and help shape the secondary endpoint to measure what matters to patients (#QOL matters)! #LCSM

Great to see @jillfeldman4 present results from #COCOON here at #ASCO25 on quality of life and prevention of skin reactions. At @JNJInnovMed we work collaboratively with all in the medical community to advance care for patients. #MyCompany

My favorite way to start my conference every year. So excited to see all the new data presented and so many friends at #ASCO2025

Looking forward to sharing the story of how the @JNJInnovMed team working in partnership with the medical community @szusmani @mvmateos @cbcbc1971 has been at the forefront of innovation in developing bispecifics in oncology. Register to join. #MyCompany https://t.co/c1eXX2muPP

Proud to share my latest podcast episode. Meet @Jbauml He has great story & doing great work for the cancer community @JNJInnovMed @MAWildgust @PolishRunner84 @BKenney1 @RebeccaGenin @RitaRibeiroMBA @carolinepavis @JackieZima #lungcancer #cancerresearch https://t.co/oIvcTiNfFl

Every step forward brings new hope for patients and their families. Together, we’re working to change what’s possible in lung cancer care: https://t.co/zkfLH6b1Zu #MyCompany #JNJOncology #ELCC2025

Exciting news in Europe! The CHMP recommends our subcutaneous therapy for patients with advanced #NSCLC with certain EGFR mutations. Read about this potential new option that can improve the treatment experience for patients: https://t.co/KMSOiJA6en

Today, we’re one step closer to transforming care for EGFRm #NSCLC. I’m excited to share that the European Commission has now fully approved our chemo-free regimen—a breakthrough that offers a new way forward for patients and their families across the EU: https://t.co/MKWoZbODzj

Update on #Mariposa study for #EGFR #NSCLC from @JNJInnovation. Providing more hope for patients. #MyCompany https://t.co/jDnHmQQGhW

🚨Major breakthrough from #PressRelease The MARIPOSA study reports a statistically significant and clinically meaningful improvement in overall survival (OS), reshaping the treatment landscape for patients with EGFR mutant NSCLC 🚀 https://t.co/QYBzGiKrgJ

Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce @JNJInnovMed’s dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: https://t.co/Ug1aHpoqJP

Excited to announce the European Commission approved our chemotherapy-free combination therapy for the first-line treatment of EGFRm #NSCLC. Proud to be part of a team at #JNJOncology that continues to drive innovation for patients. https://t.co/5tpp9hepug

Exciting progress for patients in Europe! A CHMP positive opinion brings us closer to offering the first chemotherapy-free combination therapy for first-line treatment of EGFRm #NSCLC. Proud to be part of the journey to redefine standards of care. https://t.co/yZ9E4mtNdi

Getting #InFrontofCancer means recognizing the current standard of care is not enough for our patients – they deserve more. This #LungCancerAwarenessMonth, I’m honored to share what drives my passion to get in front of this disease: https://t.co/negWcJdFW1

#NEWS: The U.S. FDA has approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. Learn more here: https://t.co/xo3SRuiBaH #JNJOncology

The U.S. FDA approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. This milestone marks @JNJInnovMed’s third new indication in six months for this targeted therapy: https://t.co/idwHB2Vxdn